Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

NCT00667394 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

Glioblastoma
Gliosarcoma
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Mixed Oligoastrocytoma

Interventions

BIOLOGICAL: Bevacizumab
DRUG: MLN-518 (Tandutinib)
PROCEDURE: Quality-of-life assessment

Sponsor

National Cancer Institute (NCI)